Reversal of Feminisation/Masculinisation & Return of Natural Hormones

Reversal of Feminisation/Masculinisation & Return of Natural Hormones


Introduction:
Gender-affirming care plays a crucial role in supporting individuals' gender identities through interventions such as hormone therapy. However, there are circumstances where individuals may choose to discontinue gender-affirming treatments. In this article, we explore the effects of stopping gender-affirming care, including the reversal of feminization or masculinization and the potential return of natural hormone production.

Understanding Gender-Affirming Care:
Gender-affirming care encompasses a range of medical interventions aimed at aligning an individual's physical characteristics with their gender identity. Hormone therapy, including testosterone for masculinization and estrogen for feminization, is a cornerstone of gender-affirming treatment for many transgender and non-binary individuals.

Discontinuing Medication

The process of discontinuing gender-affirming medication can be tailored to an individual's needs and preferences. There are no rigid guidelines dictating a specific timeline or pace for this transition. Each person's journey is unique, and it's entirely acceptable to adjust the dosage or discontinue medication as slowly or as quickly as feels comfortable and right.

Reversal of Feminization or Masculinization:
When individuals discontinue hormone therapy, whether due to personal choice, medical concerns, or other reasons, they may experience a reversal of the physical changes induced by the hormones. For example, transgender women who stop estrogen therapy may notice a reversal of breast development, softening of skin, and redistribution of body fat. Similarly, transgender men who cease testosterone therapy may experience a reversal of voice deepening, facial hair growth, and muscle mass increase.

Reversibility of Secondary Sex Characteristics:
The reversibility of secondary sex characteristics largely depends on the type of gender-affirming care received, the duration of treatment, and individual factors such as age, genetics, and overall health. While some changes may partially or fully regress upon discontinuation of treatment, others may be irreversible.

Timelines for Regression:
The timeline for regression varies among individuals and may be influenced by factors such as the duration of hormone therapy, dosage, and age at initiation of treatment. Below is a general overview of timelines for regression based on common secondary sex characteristics:

Secondary Sex CharacteristicTimelines for Regression upon Stopping Hormone Therapy
Facial Hair Growth (Testosterone)Partial regression may occur within several months, with further reduction over 1-2 years. Complete regression may take longer. or may not be achieved.
Breast Development (Estrogen)Breast tissue may gradually decrease in size over several months to years, with significant regression typically observed within 6-12 months. Complete regression may take longer or may not be achieved.
Body Fat RedistributionRedistribution of body fat may reverse over several months to years upon cessation of hormone therapy, resulting in a more masculine or feminine distribution depending on the individual's assigned sex at birth.
Voice Changes (Testosterone)Vocal changes induced by testosterone may regress partially but often remain lower than pre-treatment levels. Complete regression to pre-treatment pitch is rare.
Menstrual Cycle Suppression (Testosterone)Menstrual cycles may resume within a few months to a year after stopping testosterone therapy. Regularity and fertility may vary among individuals.

Aspects that may Regress:

  • Body Fat Redistribution: Changes in fat distribution typically regress, leading to a return to a more masculine or feminine pattern depending on the individual's assigned sex at birth.
  • Breast Development: Breast tissue may decrease in size, with regression varying in degree and timeline among individuals.
  • Facial Hair Growth: Facial hair growth induced by testosterone may decrease, although complete regression is less common.
  • Voice Changes: Vocal changes may partially regress, but the voice usually remains lower than pre-treatment levels.

Aspects that may not Regress:

  • Voice Changes: Complete regression to pre-treatment pitch is rare, and some deepening of the voice may persist even after discontinuation of testosterone therapy.
  • Bone Structure: Changes in bone structure, such as widening of the pelvis or facial bone growth, are generally irreversible.
  • Reproductive Function: Fertility may not fully return after prolonged hormone therapy, and some individuals may experience permanent infertility.

The reversibility of secondary sex characteristics upon discontinuation of gender-affirming care is a complex and individualized process. While some changes may partially or fully regress, others may be irreversible. Understanding the timelines and factors involved in regression is essential for individuals considering gender-affirming treatments. Healthcare providers play a crucial role in discussing these aspects with individuals and providing support throughout the treatment process.

Return of Natural Hormone Production:
Upon discontinuation of hormone therapy, the body may gradually resume its natural hormone production patterns. This process can vary widely among individuals and depends on factors such as the duration of hormone therapy, age, and overall health. Some individuals may experience a relatively swift return to their pre-treatment hormone levels, while others may require a more extended period for natural hormone production to resume fully.

Clearance Times:

MedicationApproximate Clearance Time
Estrogen1-2 days (short-acting) to several weeks (long-acting)
Testosterone3-4 days (short-acting) to several weeks (long-acting)
Finasteride4-6 days
Spironolactone1-2 days
GnRH Agonists (GnRHa)Several weeks to months (due to depot formulations)
Cyproterone Acetate1-2 days

Please note that these clearance times are approximate and can vary depending on individual factors such as metabolism, dosage, duration of use, and formulation. Additionally, some medications, particularly GnRH agonists and certain long-acting formulations, may have a more extended clearance time due to their depot effect or prolonged action within the body.

Psychological and Emotional Considerations:
The decision to stop gender-affirming care can have psychological and emotional implications for individuals. For some, it may represent a reevaluation of their gender identity or a desire to explore alternative paths of gender expression. Others may experience distress or dysphoria related to the physical changes associated with discontinuing hormone therapy. Access to mental health support and affirming care providers is essential during this transition period.

Medical Monitoring and Support:
Healthcare providers play a crucial role in supporting individuals who choose to discontinue gender-affirming care. Close medical monitoring, including regular assessments of physical and mental health, can help identify and address any concerns or complications that may arise during the transition process. Additionally, healthcare providers can offer guidance on managing symptoms, exploring alternative treatments, and accessing supportive resources within the transgender and non-binary community.

Conclusion:
The decision to stop gender-affirming care is deeply personal and multifaceted, influenced by various factors including individual preferences, medical considerations, and social contexts. Understanding the potential effects of discontinuing hormone therapy, including the reversal of physical changes and the return of natural hormone production, is crucial for both individuals and healthcare providers. By providing comprehensive support and affirming care, we can empower individuals to navigate their gender journeys with dignity, respect, and autonomy.


    • Related Articles

    • Feminisation Hormone Therapy An Overview

      Introduction Feminisation hormone therapy is a cornerstone in the journey of transgender women and transfeminine individuals. It involves the use of hormones to induce physical changes that align with one’s gender identity. This transformative ...
    • Masculinisation Hormone Therapy An overview

      Introduction Masculinisation hormone therapy marks a significant milestone in the transition journey for many transgender men and transmasculine individuals. It’s a process that involves more than just physical transformation; it’s a deeply personal ...
    • Skeletal Growth and Masculinisation

      The effects of masculinisation through hormone therapy, particularly testosterone, on the skeleton can vary depending on several factors, including age and the timing of treatment in relation to the closure of growth plates (epiphyseal plates) in the ...
    • Expected Timeframes for Masculinisation During Hormone Therapy

      Masculinisation hormone therapy is a cornerstone for many transgender men and transmasculine individuals in their transition journey. It involves administering testosterone, which brings about physical changes aligned with one’s gender identity. ...
    • Expected Timeframes for Feminisation During Hormone Therapy

      Here is an infographic that visually represents the expected timeframes for feminisation during hormone therapy. This graphic includes key milestones along the timeline, detailing changes you can typically expect during different stages of the ...